{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:22:07Z","timestamp":1772216527430,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Infarct size is a major prognostic factor in ST-segment elevation myocardial infarction (STEMI). It is often assessed using repeated blood sampling and the estimation of biomarker area under the concentration versus time curve (AUC) in translational research. We aimed at developing limited sampling strategies (LSS) to accurately estimate biomarker AUC using only a limited number of blood samples in STEMI patients. This retrospective study was carried out on pooled data from five clinical trials of STEMI patients (TIMI blood flow 0\/1) studies where repeated blood samples were collected within 72\u00a0h after admission to assess creatine kinase (CK), cardiac troponin I (cTnI) and muscle-brain CK (CK-MB). Biomarker kinetics was assessed using previously described biomarker kinetic models. A number of LSS models including combinations of 1 to 3 samples were developed to identify sampling times leading to the best estimation of AUC. Patients were randomly assigned to either learning (2\/3) or validation (1\/3) subsets. Descriptive and predictive performances of LSS models were compared using learning and validation subsets, respectively. An external validation cohort was used to validate the model and its applicability to different cTnI assays, including high-sensitive (hs) cTnI. 132 patients had full CK and cTnI dataset, 49 patients had CK-MB. For each biomarker, 180 LSS models were tested. Best LSS models were obtained for the following sampling times: T4\u201316 for CK, T8\u2013T20 for cTnI and T8\u2013T16 for CK-MB for 2-sample LSS; and T4\u2013T16\u2013T24 for CK, T4\u2013T12\u2013T20 for cTnI and T8\u2013T16\u2013T20 for CK-MB for 3-sample LSS. External validation was achieved on 103 anterior STEMI patients (TIMI flow 0\/1), and the cTnI model applicability to recommended hs cTnI confirmed. Biomarker kinetics can be assessed with a limited number of samples using kinetic modelling. This opens the way for substantial simplification of future cardioprotection studies, more acceptable for the patients.<\/jats:p>","DOI":"10.1038\/s41598-020-70501-4","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T10:06:55Z","timestamp":1597226815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Kinetic modelling of myocardial necrosis biomarkers offers an easier, reliable and more acceptable assessment of infarct size"],"prefix":"10.1038","volume":"10","author":[{"given":"St\u00e9phanie","family":"Chadet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ternant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Roubille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodora","family":"Bejan-Angoulvant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Prunier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Mewton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Paintaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Ovize","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marie","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Angoulvant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2407-6387","authenticated-orcid":false,"given":"Fabrice","family":"Ivanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"70501_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1161\/01.cir.59.1.113","volume":"59","author":"PL Thompson","year":"1979","unstructured":"Thompson, P. L., Fletcher, E. E. & Katavatis, V. Enzymatic indices of myocardial necrosis: Influence on short- and long-term prognosis after myocardial infarction. Circulation59, 113\u2013119. https:\/\/doi.org\/10.1161\/01.cir.59.1.113 (1979).","journal-title":"Circulation"},{"key":"70501_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/01.cir.79.2.441","volume":"79","author":"E Braunwald","year":"1989","unstructured":"Braunwald, E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?. Circulation79, 441\u2013444. https:\/\/doi.org\/10.1161\/01.cir.79.2.441 (1989).","journal-title":"Circulation"},{"key":"70501_CR3","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/eurheartj\/ehw145","volume":"38","author":"DJ Hausenloy","year":"2017","unstructured":"Hausenloy, D. J. et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: Trials and tribulations. Eur. Heart J.38, 935\u2013941. https:\/\/doi.org\/10.1093\/eurheartj\/ehw145 (2017).","journal-title":"Eur. Heart J."},{"key":"70501_CR4","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/eurheartj\/ehw224","volume":"38","author":"G Heusch","year":"2017","unstructured":"Heusch, G. & Gersh, B. J. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: A continual challenge. Eur. Heart J.38, 774\u2013784. https:\/\/doi.org\/10.1093\/eurheartj\/ehw224 (2017).","journal-title":"Eur. Heart J."},{"key":"70501_CR5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/CIRCRESAHA.116.308736","volume":"119","author":"G Heusch","year":"2016","unstructured":"Heusch, G. & Rassaf, T. Time to give up on cardioprotection? A critical appraisal of clinical studies on ischemic pre-, post-, and remote conditioning. Circ. Res.119, 676\u2013695. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308736 (2016).","journal-title":"Circ. Res."},{"key":"70501_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00395-018-0696-8","volume":"113","author":"HE B\u00f8tker","year":"2018","unstructured":"B\u00f8tker, H. E. et al. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res. Cardiol.113, 39. https:\/\/doi.org\/10.1007\/s00395-018-0696-8 (2018).","journal-title":"Basic Res. Cardiol."},{"key":"70501_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","volume":"127","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara, P. T. et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: Executive summary: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation127, 529\u2013555. https:\/\/doi.org\/10.1161\/CIR.0b013e3182742c84 (2013).","journal-title":"Circulation"},{"key":"70501_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","volume":"40","author":"K Thygesen","year":"2019","unstructured":"Thygesen, K. et al. Fourth universal definition of myocardial infarction (2018). Eur. Heart J.40, 237\u2013269. https:\/\/doi.org\/10.1093\/eurheartj\/ehy462 (2019).","journal-title":"Eur. Heart J."},{"key":"70501_CR9","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1172\/JCI109004","volume":"61","author":"SF Vatner","year":"1978","unstructured":"Vatner, S. F., Baig, H., Manders, W. T. & Maroko, P. R. Effects of coronary artery reperfusion on myocardial infarct size calculated from creatine kinase. J. Clin. Investig.61, 1048\u20131056. https:\/\/doi.org\/10.1172\/JCI109004 (1978).","journal-title":"J. Clin. Investig."},{"key":"70501_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000173283","volume":"68","author":"R Nordlander","year":"1981","unstructured":"Nordlander, R., Nyquist, O. & Sylv\u00e9n, C. Estimation of infarct size by creatine kinase. A comparison between maximal value, planimetry and computer calculation. Cardiology68, 201\u2013205. https:\/\/doi.org\/10.1159\/000173283 (1981).","journal-title":"Cardiology"},{"key":"70501_CR11","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jacc.2004.06.071","volume":"44","author":"RJ Gibbons","year":"2004","unstructured":"Gibbons, R. J., Valeti, U. S., Araoz, P. A. & Jaffe, A. S. The quantification of infarct size. J. Am. Coll. Cardiol.44, 1533\u20131542. https:\/\/doi.org\/10.1016\/j.jacc.2004.06.071 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"70501_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/01.cir.52.5.743","volume":"52","author":"R Roberts","year":"1975","unstructured":"Roberts, R., Henry, P. D. & Sobel, B. E. An improved basis for enzymatic estimation of infarct size. Circulation52, 743\u2013754. https:\/\/doi.org\/10.1161\/01.cir.52.5.743 (1975).","journal-title":"Circulation"},{"key":"70501_CR13","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1161\/CIRCULATIONAHA.105.558122","volume":"112","author":"P Staat","year":"2005","unstructured":"Staat, P. et al. Postconditioning the human heart. Circulation112, 2143\u20132148. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.558122 (2005).","journal-title":"Circulation"},{"key":"70501_CR14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s00395-013-0400-y","volume":"109","author":"F Prunier","year":"2014","unstructured":"Prunier, F. et al. The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction. Basic Res. Cardiol.109, 400. https:\/\/doi.org\/10.1007\/s00395-013-0400-y (2014).","journal-title":"Basic Res. Cardiol."},{"key":"70501_CR15","doi-asserted-by":"publisher","first-page":"10709","DOI":"10.1038\/s41598-017-11352-4","volume":"7","author":"D Ternant","year":"2017","unstructured":"Ternant, D. et al. Revisiting myocardial necrosis biomarkers: Assessment of the effect of conditioning therapies on infarct size by kinetic modelling. Sci. Rep.7, 10709. https:\/\/doi.org\/10.1038\/s41598-017-11352-4 (2017).","journal-title":"Sci. Rep."},{"key":"70501_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1056\/NEJMoa071142","volume":"359","author":"C Piot","year":"2008","unstructured":"Piot, C. et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N. Engl. J. Med.359, 473\u2013481. https:\/\/doi.org\/10.1056\/NEJMoa071142 (2008).","journal-title":"N. Engl. J. Med."},{"key":"70501_CR17","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1161\/CIRCULATIONAHA.107.729780","volume":"117","author":"H Thibault","year":"2008","unstructured":"Thibault, H. et al. Long-term benefit of postconditioning. Circulation117, 1037\u20131044. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.729780 (2008).","journal-title":"Circulation"},{"key":"70501_CR18","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.jacc.2012.03.026","volume":"59","author":"F Thuny","year":"2012","unstructured":"Thuny, F. et al. Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol.59, 2175\u20132181. https:\/\/doi.org\/10.1016\/j.jacc.2012.03.026 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"70501_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00395-013-0383-8","volume":"108","author":"N Mewton","year":"2013","unstructured":"Mewton, N. et al. Postconditioning attenuates no-reflow in STEMI patients. Basic Res. Cardiol.108, 383. https:\/\/doi.org\/10.1007\/s00395-013-0383-8 (2013).","journal-title":"Basic Res. Cardiol."},{"key":"70501_CR20","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/jps.2600711209","volume":"71","author":"LB Sheiner","year":"1982","unstructured":"Sheiner, L. B. & Beal, S. L. Bayesian individualization of pharmacokinetics: Simple implementation and comparison with non-Bayesian methods. J. Pharm. Sci.71, 1344\u20131348. https:\/\/doi.org\/10.1002\/jps.2600711209 (1982).","journal-title":"J. Pharm. Sci."},{"key":"70501_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/01.ftd.0000162231.90811.38","volume":"27","author":"A Pr\u00e9maud","year":"2005","unstructured":"Pr\u00e9maud, A. et al. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit27, 354\u2013361. https:\/\/doi.org\/10.1097\/01.ftd.0000162231.90811.38 (2005).","journal-title":"Ther Drug Monit"},{"key":"70501_CR22","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.phrs.2015.07.012","volume":"99","author":"J-B Woillard","year":"2015","unstructured":"Woillard, J.-B. et al. Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients. Pharmacol. Res.99, 308\u2013315. https:\/\/doi.org\/10.1016\/j.phrs.2015.07.012 (2015).","journal-title":"Pharmacol. Res."},{"key":"70501_CR23","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2125.2010.03615.x","volume":"69","author":"W Zhao","year":"2010","unstructured":"Zhao, W. et al. Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. Br. J. Clin. Pharmacol.69, 358\u2013366. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03615.x (2010).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"70501_CR24","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/2048872615585518","volume":"5","author":"G Laugaudin","year":"2016","unstructured":"Laugaudin, G. et al. Kinetics of high-sensitivity cardiac troponin T and I differ in patients with ST-segment elevation myocardial infarction treated by primary coronary intervention. Eur. Heart J. Acute Cardiovasc. Care5, 354\u2013363. https:\/\/doi.org\/10.1177\/2048872615585518 (2016).","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"70501_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10928-018-9579-8","volume":"45","author":"AHM de Vries Schultink","year":"2018","unstructured":"de Vries Schultink, A. H. M. et al. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens. J. Pharmacokinet. Pharmacodyn.45, 431\u2013442. https:\/\/doi.org\/10.1007\/s10928-018-9579-8 (2018).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"70501_CR26","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03891.x","volume":"71","author":"SB Duffull","year":"2011","unstructured":"Duffull, S. B., Wright, D. F. B. & Winter, H. R. Interpreting population pharmacokinetic-pharmacodynamic analyses\u2014A clinical viewpoint. Br. J. Clin. Pharmacol.71, 807\u2013814. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03891.x (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"70501_CR27","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1038\/psp.2012.4","volume":"1","author":"DR Mould","year":"2012","unstructured":"Mould, D. R. & Upton, R. N. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometr. Syst. Pharmacol.1, e6. https:\/\/doi.org\/10.1038\/psp.2012.4 (2012).","journal-title":"CPT Pharmacometr. Syst. Pharmacol."},{"key":"70501_CR28","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould, D. R. & Upton, R. N. Basic concepts in population modeling, simulation, and model-based drug development-part 2: Introduction to pharmacokinetic modeling methods. CPT Pharmacometr. Syst. Pharmacol.2, e38. https:\/\/doi.org\/10.1038\/psp.2013.14 (2013).","journal-title":"CPT Pharmacometr. Syst. Pharmacol."},{"key":"70501_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/BF01061728","volume":"5","author":"LB Sheiner","year":"1977","unstructured":"Sheiner, L. B., Rosenberg, B. & Marathe, V. V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J. Pharmacokinet. Biopharm.5, 445\u2013479. https:\/\/doi.org\/10.1007\/BF01061728 (1977).","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"70501_CR30","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1161\/CIRCULATIONAHA.117.030798","volume":"136","author":"E Puymirat","year":"2017","unstructured":"Puymirat, E. et al. Acute myocardial infarction: Changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FAST-MI program (French Registry of acute ST-elevation or Non-ST-elevation myocardial infarction) 1995 to 2015. Circulation136, 1908\u20131919. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030798 (2017).","journal-title":"Circulation"},{"key":"70501_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1161\/01.cir.56.2.199","volume":"56","author":"WJ Rogers","year":"1977","unstructured":"Rogers, W. J. et al. Correlation of angiographic estimates of myocardial infarct size and accumulated release of creatine kinase MB isoenzyme in man. Circulation56, 199\u2013205. https:\/\/doi.org\/10.1161\/01.cir.56.2.199 (1977).","journal-title":"Circulation"},{"key":"70501_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1161\/01.cir.60.1.130","volume":"60","author":"M Rigaud","year":"1979","unstructured":"Rigaud, M. et al. Regional left ventricular function assessed by contrast angiography in acute myocardial infarction. Circulation60, 130\u2013139. https:\/\/doi.org\/10.1161\/01.cir.60.1.130 (1979).","journal-title":"Circulation"},{"key":"70501_CR33","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0002-8703(03)00112-1","volume":"145","author":"AC Lapeyre","year":"2003","unstructured":"Lapeyre, A. C., St Gibson, W., Bashore, T. M. & Gibbons, R. J. Quantitative regional wall motion analysis with early contrast ventriculography for the assessment of myocardium at risk in acute myocardial infarction. Am. Heart J.145, 1051\u20131057. https:\/\/doi.org\/10.1016\/S0002-8703(03)00112-1 (2003).","journal-title":"Am. Heart J."},{"key":"70501_CR34","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/01.cir.46.4.679","volume":"46","author":"BJ Feild","year":"1972","unstructured":"Feild, B. J., Russell, R. O., Dowling, J. T. & Rackley, C. E. Regional left ventricular performance in the year following myocardial infarction. Circulation46, 679\u2013689. https:\/\/doi.org\/10.1161\/01.cir.46.4.679 (1972).","journal-title":"Circulation"},{"key":"70501_CR35","unstructured":"R Core Team. R: A language and environment for statistical computing. (R Foundation for Statistical Computing, Vienna, Austria, 2014). https:\/\/www.R-project.org."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70501-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70501-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70501-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T15:22:22Z","timestamp":1670340142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70501-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["70501"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-70501-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"27 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13597"}}